: We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39-3.02, p < 0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18-0.99, p = 0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon.
Sormani, M.p., Salvetti, M., Labauge, P., Schiavetti, I., Zephir, H., Carmisciano, L., et al. (2021). DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 8(8), 1738-1744 [10.1002/acn3.51408].
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France
Marfia G. A.
2021-08-01
Abstract
: We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39-3.02, p < 0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18-0.99, p = 0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon.| File | Dimensione | Formato | |
|---|---|---|---|
|
ACN3-8-1738.pdf
accesso aperto
Licenza:
Creative commons
Dimensione
321.4 kB
Formato
Adobe PDF
|
321.4 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
